Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 757-760

  Carruthers, Robert L ^a,b   Chitnis, Tanuja ^a,b   Healy, Brian C ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

disease modifying therapies; JC Virus; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

NATALIZUMAB; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ABNORMAL LABORATORY RESULT; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; GOLD STANDARD; HUMAN; INFECTION RISK; JC VIRUS; NATALIZUMAB ASSOCIATED JC VIURS SERO NEGATIVE PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROBABILITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; STATISTICAL MODEL; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; RISK FACTOR; BINOMIAL DISTRIBUTION; BIOLOGICAL MODEL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; MAJOR CLINICAL STUDY; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; PROBABILITY; RISK FACTORS;

EID: 84899125270     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513509509     Document Type: Article

References (7)

1. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366: 1870-80
2. PML incidence in patients receiving Tysabri (natalizumab). Biogen Idec; 2013 [updated 7/14/2013 ]; Available from: http://medinfo.biogenidec.com/
3. Berger JR, Houff SA, Gurwell J, et al. JC virus antibody status underestimates infection rates. Ann Neurol. 2013 ; 74 (1). 84-90
4. Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013 ; 368: 2240-1
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
6. Plavina T Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients. Orlando, FL: Consortium of Multiple Sclerosis Centers ; 2013 :
7. Laroni A, Giacomazzi CG, Grimaldi L, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012 ; 7: 665-72